Biodexa Pharmaceticals Financials

BDRX Stock   4.16  0.24  5.45%   
Based on the key indicators related to Biodexa Pharmaceticals' liquidity, profitability, solvency, and operating efficiency, Biodexa Pharmaceticals is not in a good financial situation at this time. It has a very high odds of going through financial crisis in February. At this time, Biodexa Pharmaceticals' Capital Stock is fairly stable compared to the past year. Current Deferred Revenue is likely to rise to about 1.1 M in 2025, whereas Total Assets are likely to drop slightly above 9 M in 2025. Key indicators impacting Biodexa Pharmaceticals' financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Debt Equity Ratio0.110.0992
Significantly Up
Slightly volatile
Current Ratio1.381.45
Notably Down
Very volatile
Investors should never underestimate Biodexa Pharmaceticals' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Biodexa Pharmaceticals' cash flow, debt, and profitability to make informed and accurate decisions about investing in Biodexa Pharmaceticals.

Net Income

(6.69 Million)

  
Understanding current and past Biodexa Pharmaceticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Biodexa Pharmaceticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Biodexa Pharmaceticals' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Biodexa Pharmaceticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Biodexa Pharmaceticals. Check Biodexa Pharmaceticals' Beneish M Score to see the likelihood of Biodexa Pharmaceticals' management manipulating its earnings.

Biodexa Pharmaceticals Stock Summary

Biodexa Pharmaceticals competes with Ziff Davis, Acumen Pharmaceuticals, Disney, Spyre Therapeutics, and Alvotech. Biodexa Pharmaceticals is entity of United States. It is traded as Stock on NASDAQ exchange.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
CUSIP59564R302 59564R104 59564R708 59564R203 59564R609 59564R500 59564R807
LocationUnited Kingdom
Business Address1 Caspian Point,
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.biodexapharma.com
Phone44 29 2048 0180

Biodexa Pharmaceticals Key Financial Ratios

Biodexa Pharmaceticals Key Balance Sheet Accounts

202020212022202320242025 (projected)
Total Assets9.8M12.9M5.5M10.5M9.5M9.0M
Other Current Liab2.4M1.2M1.3M5.0M4.5M2.5M
Net Debt(7.3M)(9.3M)(2.2M)(5.5M)(6.3M)(6.6M)
Retained Earnings(122.4M)(127.8M)(135.3M)(144.8M)(130.3M)(123.8M)
Accounts Payable337K485K339K314K282.6K268.5K
Cash7.5M10.1M2.8M6.0M5.4M8.0M
Other Current Assets258K607K376K355K319.5K303.5K
Total Liab3.1M2.5M2.4M5.9M5.3M5.8M
Total Current Assets9.3M11.8M4.7M7.0M6.3M10.0M
Intangible Assets10.1M10.1M6K2.9M2.6M2.5M
Net Receivables95K33K329K704K633.6K455.7K
Short Term Debt200K146K161K169K152.1K144.5K
Common Stock63K98.5K1.1M1.2M1.4M1.4M
Net Invested Capital6.8M10.5M3.2M4.7M4.2M7.9M
Capital Stock63K98.5K1.1M1.2M1.4M1.4M
Net Working Capital6.3M9.9M2.8M1.5M1.3M1.2M

Biodexa Pharmaceticals Key Income Statement Accounts

An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
202020212022202320242025 (projected)
Operating Income(10.7M)(7.0M)(8.9M)(8.0M)(7.2M)(7.6M)
Ebit(23.4M)(6.1M)(7.7M)(7.4M)(6.7M)(7.0M)
Research Development16.1M4.7M5.1M4.1M4.7M7.6M
Ebitda(22.2M)(5.7M)(7.4M)(7.2M)(6.4M)(6.8M)
Income Before Tax(23.5M)(6.1M)(8.5M)(7.5M)(6.7M)(7.1M)
Net Income(22.2M)(5.5M)(7.7M)(7.1M)(6.4M)(6.7M)
Income Tax Expense1.3M646K832K(406K)(365.4K)(347.1K)
Total Revenue343K578K699K381K342.9K625.7K
Gross Profit(5.7M)(4.1M)(4.4M)(3.7M)(3.3M)(3.5M)
Cost Of Revenue6.1M4.7M5.1M4.1M3.7M4.7M
Tax Provision(1.3M)(646K)(832K)(406K)(466.9K)(490.2K)
Net Interest Income(33K)(44K)(24K)42K48.3K50.7K
Interest Income1K0.029K83K95.5K100.2K
Interest Expense34K44K53K41K36.9K43.0K

Biodexa Pharmaceticals Key Cash Accounts

Cash flow analysis captures how much money flows into and out of Biodexa Pharmaceticals. It measures of how well Biodexa is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Biodexa Pharmaceticals brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Biodexa had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Biodexa Pharmaceticals has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
202020212022202320242025 (projected)
Change In Cash(3.4M)2.5M(7.2M)3.1M2.8M3.0M
Free Cash Flow(9.5M)(6.3M)(7.1M)(7.1M)(6.4M)(6.7M)
Depreciation1.2M403K343K283K254.7K242.0K
Other Non Cash Items430K(892K)454K397K357.3K603.6K
Capital Expenditures209K320K62K263K236.7K380.6K
Net Income(22.2M)(5.5M)(7.7M)(7.1M)(6.4M)(6.7M)
End Period Cash Flow7.5M10.1M2.8M6.0M5.4M8.0M
Investments2.6M(278K)(220K)(265K)(304.8K)(320.0K)

Biodexa Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Biodexa Pharmaceticals's current stock value. Our valuation model uses many indicators to compare Biodexa Pharmaceticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Biodexa Pharmaceticals competition to find correlations between indicators driving Biodexa Pharmaceticals's intrinsic value. More Info.
Biodexa Pharmaceticals is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . At this time, Biodexa Pharmaceticals' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Biodexa Pharmaceticals' earnings, one of the primary drivers of an investment's value.

Biodexa Pharmaceticals Systematic Risk

Biodexa Pharmaceticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Biodexa Pharmaceticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Biodexa Pharmaceticals correlated with the market. If Beta is less than 0 Biodexa Pharmaceticals generally moves in the opposite direction as compared to the market. If Biodexa Pharmaceticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Biodexa Pharmaceticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Biodexa Pharmaceticals is generally in the same direction as the market. If Beta > 1 Biodexa Pharmaceticals moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Biodexa Pharmaceticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Biodexa Pharmaceticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Biodexa Pharmaceticals growth as a starting point in their analysis.

Price Earnings To Growth Ratio

0.00348

At this time, Biodexa Pharmaceticals' Price Earnings To Growth Ratio is fairly stable compared to the past year.

Biodexa Pharmaceticals January 23, 2025 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Biodexa Pharmaceticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Biodexa Pharmaceticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Biodexa Pharmaceticals based on widely used predictive technical indicators. In general, we focus on analyzing Biodexa Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Biodexa Pharmaceticals's daily price indicators and compare them against related drivers.

Additional Tools for Biodexa Stock Analysis

When running Biodexa Pharmaceticals' price analysis, check to measure Biodexa Pharmaceticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biodexa Pharmaceticals is operating at the current time. Most of Biodexa Pharmaceticals' value examination focuses on studying past and present price action to predict the probability of Biodexa Pharmaceticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biodexa Pharmaceticals' price. Additionally, you may evaluate how the addition of Biodexa Pharmaceticals to your portfolios can decrease your overall portfolio volatility.